dichlororibofuranosylbenzimidazole has been researched along with Adenocarcinoma in 2 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shan, B | 1 |
| Zhuo, Y | 1 |
| Chin, D | 1 |
| Morris, CA | 1 |
| Morris, GF | 1 |
| Lasky, JA | 1 |
| te Poele, RH | 1 |
| Okorokov, AL | 1 |
| Joel, SP | 1 |
2 other studies available for dichlororibofuranosylbenzimidazole and Adenocarcinoma
| Article | Year |
|---|---|
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Culture Media, Conditioned; Cyclin T; Cyclin-Dependent Kinase 9; C | 2005 |
RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Cell Survival; Clone Cells; Colonic Neoplasms; Dichlororibofuranosylbenzi | 1999 |